Table 2. Clinical adverse events according to the neointimal characteristics at 40.0 months after OCT evaluation.
Homogeneous neointima | Heterogeneous neointima | Layered neointima | p-value | |
---|---|---|---|---|
n = 207 (54.9%) | n = 93 (24.7%) | n = 77 (20.4%) | ||
Non-TLR | 18 (8.7%) | 13 (14.0%) | 6 (7.8%) | 0.114 |
Cardiac death | 4 (1.9%) | 1 (1.1%) | 0 (0%) | 0.588 |
Any MI | 1 (0.5%) | 3 (3.2%) | 2 (2.6%) | 0.093 |
TLR | 6 (2.9%) | 18 (19.4%) | 8 (10.4%) | <0.001 |
Any revascularization | 22 (10.6%) | 28 (30.1%) | 10 (13.0%) | <0.001 |
Data are presented as number (%). MI, myocardial infarction; Non-TLR, non-target lesion revascularization; OCT, optical coherence tomography; TLR, target lesion revascularization